Justin Vogel - 03 Jan 2023 Form 3 Insider Report for Provention Bio, Inc.

Role
Chief Accounting Officer
Signature
/s/ Thierry Chauche, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
3
Filing time
05 Jan 2023, 15:26:46 UTC
Next filing
11 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRVB Stock Option (right to buy) 03 Jan 2023 Common Stock 88,185 $4.00 Direct F1
holding PRVB Stock Option (right to buy) 03 Jan 2023 Common Stock 45,000 $12.54 Direct F2
holding PRVB Stock Option (right to buy) 03 Jan 2023 Common Stock 60,000 $12.62 Direct F3
holding PRVB Stock Option (right to buy) 03 Jan 2023 Common Stock 66,000 $6.80 Direct F4
holding PRVB Stock Option (right to buy) 03 Jan 2023 Common Stock 70,000 $4.39 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 19, 2018, the Reporting Person was granted a stock option for 103,185 shares of Common Stock, 41,274 of which vested in four equal annual installments commencing on June 1, 2019, and 61,911 of which were granted with performance-based vesting triggers, which have all vested based on the satisfaction of certain performance milestones. In December 2019, the Reporting Person exercised 15,000 of the shares and sold them on a cashless basis. The stock options were granted pursuant to the Issuer's 2017 Equity Incentive Plan.
F2 On June 24, 2019, the Reporting Person was granted a stock option for 45,000 shares of Common Stock which will vest as follows: 25% vested and became exercisable on June 24, 2020, and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on June 24, 2023. The stock options were granted pursuant to the Issuer's 2017 Equity Incentive Plan.
F3 On July 15, 2020, the Reporting Person was granted a stock option for 60,000 shares of Common Stock which will vest as follows: 25% vested and became exercisable on July 15, 2021, and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on July 15, 2024. The stock options were granted pursuant to the Issuer's 2017 Equity Incentive Plan.
F4 On May 12, 2021, the Reporting Person was granted a stock option for 66,000 shares of Common Stock which will vest as follows: 25% vested and became exercisable on May 12, 2022, and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The stock options were granted pursuant to the Issuer's 2017 Equity Incentive Plan.
F5 On January 18, 2022, the Reporting Person was granted a stock option for 70,000 shares of Common Stock which will vest as follows: 25% will vest and become exercisable on January 18, 2023, and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on January 18, 2026. The stock options were granted pursuant to the Issuer's 2017 Equity Incentive Plan.

Remarks:

Exhibit 24.1 - Power of Attorney